washington (reuters) – the supreme court has reduced the time it takes for a drug to reach the market biosimilars, as part of a major decision with respect to a class of medicines that can be particularly onerous, billions of dollars of business for pharmaceutical companies.
the nine judges unanimously reversed the lower court’s decision to require that the swiss pharmaceutical group company to wait six months after the approval of the food and drug administration (fda) before starting to sell its version biosimilar drug neupogen the competitor based in california, is.
a biosimilar is a medicine that contains the active substance of a version of a biological medicine that is already authorised.
the decision of the supreme court of canada has important implications for the pharmaceutical industry because it is the time that the big manufacturers of biological products may retain copies of biosimilars brand out of the market.
even six months can generate hundreds of millions of dollars of business.
for their part, insurers rely on the development of biosimilars, which are generic, a lot cheaper than brand-name drugs, allowing patients to save billions of dollars per year.
novartis said in a statement that the decision of the court “would help to speed up the access of patients to treatment that can save lives.”
on the other hand, the spokesman for amgen, kelley davenport, said the company was disappointed but that it would continue to seek to enforce its intellectual property rights against those parties that violate our rights. “
after criticizing the high prices of many drugs, president donald trump has promised to promote competition among laboratories in speeding up the procedure for authorising the placing on the market by the fda.
the action is is 0.28% to wall street to 17:00 gmt. novartis ended down 0.89% in zurich.
(andrew chung, juliet rouillon for services in french, edited by veronica poker)
copyright & copy;, thomson reuters
Translated by forexguides.info Team